Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is...
LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Feb 26, 2024 8:05am
Management Credibility
is on the line this week. My fingers are crossed that we announce first dosing on or before Feb 29, 2024. If first dosing is not announced it will be a major setback for management. I truly am
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Feb 21, 2024 8:48am
Missing Published Dates
Arch science is stellar and future potential upside is very bright but here we are today at $90 million market cap, down 40% for the year and down 60% from 2 years ago. This company has reduced the
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jan 23, 2024 11:29am
Liquidity Issues
So the Algorithms continue to dominate this stock and keep pressure on the share price from rising. We have had what I consider a number of material news releases recently along with several dating
...more
(3214)
•••
Betteryear2
X
View Profile
View Bullboard History
Comment by
Betteryear2
on Jan 10, 2024 12:27pm
RE:Arch Biopartners Receives Health Canada Approval
Sorry couldn't fit full title in. This is related to the following: No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment
...more
(3214)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Jan 10, 2024 12:23pm
Arch Biopartners Receives Health Canada Approval
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Comment by
Viking2233
on Jan 10, 2024 8:30am
RE:Material News
Well two items checked off my list beliw with Turkish Health Authority and Health Canada approvals. We are getting very close to first patient dosed and then we are off to the races. The
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jan 03, 2024 9:08am
Trial starting
Turkish final approval, AKI phade 2 trial starting! https://stockhouse.com/news/press-releases/2024/01/03/arch-biopartners-receives-approval-from-the-turkish-ministry-of-health-to
(9)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 21, 2023 8:20am
Arch Receives Ethics Committee Approval in Turkey
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide 2023-12-21 07:30:19 AM ET
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Dec 15, 2023 10:57am
Material News
This stock will continue to struggle until we receive material news. Application news will not and has not had any impact positively or negatively. We need the following: 1. Turkish Approval 2
...more
(9)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 13, 2023 7:47pm
Arch Submits Health Canada Phase II application
TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Dec 09, 2023 8:53am
Turkish Approval
The Phase 2 Kidney trial approval from Turkish authorities is taking an extremely long time for approval coupled with the fact Arch waited 12 weeks after receiving FDA approval to start the
...more
(9)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Nov 10, 2023 10:07am
Arch Biopartners - Underlying Fundamentals
Arch Biopartners is a late stage clinical trail company focused on preventing inflammation and organ injury. Arch has built a novel, therapeutic drug platform of new candidates led by LSALT
...more
(9)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Nov 04, 2023 11:13pm
Arch Biopartners - LSALT Peptide
Warren Buffet - We do not feel richer or poorer based on what the stock does, we feel richer or poorer based on what the business does: June 27, 2023 - FDA Permission to proceed with Phase
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Nov 04, 2023 3:04pm
Turkish Approval
It has been about 5 weeks since we submitted our application to start Phase 2 AKI trial to Turkish Ministry of Health. The fact we have history with doing previous phase 2 in Turkey, I anticipate news
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >